biostudies-literatureKim STKorean Health Technology R and D Project, ministru of Health and &apos;Welfare.Astra Zeneca Externally sponsored TrialSkku Excellence in Research Award 20204700-4709https://www.ebi.ac.uk/biostudies/studies/S-EPMC8974415biostudies-literatureUnknown27(17)<h4>Purpose</h4>Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein.<h4>Patients and methods</h4>Eligible patients with solid tumors, enriched for melanoma, received ceralasertib in combination with a fixed dose of paclitaxel (80 mg/m² on D1, D8, D15) in 28-day cycles. The dose of ceralasertib was escalated to reach an MTD in a rolling 6 design. The starting dose of ceralasertib was 40 mg QD. Fifty-seven patients (33 patients with melanoma who failed prior PD1/L1 treatment) were enrolled in 7 dose cohorts ranging from 40 mg QD to 240 mg BD plus weekly paclitaxel.<h4>Results</h4>The RP2D was established as ceralasertib 240 mg BD days 1-14 plus paclitaxel 80 mg/m² on D1, D8, D1Clinical cancer research : an official journal of the American Association for Cancer ResearchPhase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.PMC8974415JR20C0025Park YSBerges ASmith SASmith CKim KMKim STHong JYLee JIrurzun-Arana IPark JOLim HYWillis SLoembe ABCho HKang WKDean EKozarewa IPark SHPierce AJMortimer PfalsePhase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.<h4>Purpose</h4>Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein.<h4>Patients and methods</h4>Eligible patients with solid tumors, enriched for melanoma, received ceralasertib in combination with a fixed dose of paclitaxel (80 mg/m² on D1, D8, D15) in 28-day cycles. The dose of ceralasertib was escalated to reach an MTD in a rolling 6 design. The starting dose of ceralasertib was 40 mg QD. Fifty-seven patients (33 patients with melanoma who failed prior PD1/L1 treatment) were enrolled in 7 dose cohorts ranging from 40 mg QD to 240 mg BD plus weekly paclitaxel.<h4>Results</h4>The RP2D was established as ceralasertib 240 mg BD days 1-14 plus paclitaxel 80 mg/m² on D1, D8, D12021-01-01T00:00:00Z2021 Sep2026-07-15T01:28:11.04Z2024-11-12T18:01:35.501ZS-EPMC89744153397586210.1158/1078-0432.CCR-21-0251